Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for alpha-1 antitrypsin ...
BIF.BD Budapesti Ingatlan Hasznosítási és Fejlesztési Nyrt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback